ApiFix is slated to close a $5MM round of Series B funding by the end of 2016. Aesculap, a division of B. Braun, is investing $2.8MM in the round. Proceeds will support FDA submission and expansion of clinical and commercial activities in Europe.
The ApiFix® system for correction of Adolescent Idiopathic Scoliosis is CE Mark approved and has reached a 100-patient milestone that was announced in late 3Q16.
The minimally invasive ApiFix procedure does not require fusion. First patients who received the implant are now at four years post-op. In 2015, the company reported that results from 1- to 3-year follow-up in 50 adolescent scoliosis patients treated with ApiFix revealed substantial curve correction and no implant failure.
Sources: The Trendlines Group Ltd. and B. Braun; ORTHOWORLD Inc.
ApiFix is slated to close a $5MM round of Series B funding by the end of 2016. Aesculap, a division of B. Braun, is investing $2.8MM in the round. Proceeds will support FDA submission and expansion of clinical and commercial activities in Europe.
The ApiFix® system for correction of Adolescent Idiopathic Scoliosis is CE Mark approved and has...
ApiFix is slated to close a $5MM round of Series B funding by the end of 2016. Aesculap, a division of B. Braun, is investing $2.8MM in the round. Proceeds will support FDA submission and expansion of clinical and commercial activities in Europe.
The ApiFix® system for correction of Adolescent Idiopathic Scoliosis is CE Mark approved and has reached a 100-patient milestone that was announced in late 3Q16.
The minimally invasive ApiFix procedure does not require fusion. First patients who received the implant are now at four years post-op. In 2015, the company reported that results from 1- to 3-year follow-up in 50 adolescent scoliosis patients treated with ApiFix revealed substantial curve correction and no implant failure.
Sources: The Trendlines Group Ltd. and B. Braun; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.